Liquid Biopsy Potential Biomarkers in Prostate Cancer

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2019 Jan 31

PMID 30698162

Citations 7

Authors

Jochen Neuhaus

Bo Yang

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is the second most common cancer in men worldwide with an incidence of 14.8% and a mortality of 6.6%. Shortcomings in comprehensive medical check-ups in low- and middle-income countries lead to delayed detection of PCa and are causative of high numbers of advanced PCa cases at first diagnosis. The performance of available biomarkers is still insufficient and limited applicability, including logistical and financial burdens, impedes comprehensive implementation into health care systems. There is broad agreement on the need of new biomarkers to improve (i) early detection of PCa, (ii) risk stratification, (iii) prognosis, and (iv) treatment monitoring. This review focuses on liquid biopsy tests distinguishing high-grade significant (Gleason score (GS) ≥ 7) from low-grade indolent PCa. Available biomarkers still lack performance in risk stratification of biopsy naïve patients. However, biomarkers with highly negative predictive values may help to reduce unnecessary biopsies. Risk calculators using integrative scoring systems clearly improve decision-making for invasive prostate biopsy. Emerging biomarkers have the potential to substitute PSA and improve the overall performance of risk calculators. Until then, PSA should be used and may be replaced whenever enough evidence has accumulated for better performance of a new biomarker.

Citing Articles

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer.

Rzhevskiy A, Kapitannikova A, Butnaru D, Shpot E, Joosse S, Zvyagin A Biomedicines. 2022; 10(12).

PMID: 36551871 PMC: 9776104. DOI: 10.3390/biomedicines10123115.

Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer.

Kim J, Cho S, Park Y, Lee J, Park J PLoS One. 2021; 16(12):e0262017.

PMID: 34972164 PMC: 8719659. DOI: 10.1371/journal.pone.0262017.

MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia.

Abramovic I, Vrhovec B, Skara L, Vrtaric A, Nikolac Gabaj N, Kulis T Cancers (Basel). 2021; 13(9).

PMID: 33922968 PMC: 8123314. DOI: 10.3390/cancers13092068.

LMTK2 as Potential Biomarker for Stratification between Clinically Insignificant and Clinically Significant Prostate Cancer.

Vezelis A, Simiene J, Dabkeviciene D, Kincius M, Ulys A, Suziedelis K J Oncol. 2021; 2021:8820366.

PMID: 33488712 PMC: 7803409. DOI: 10.1155/2021/8820366.

Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.

Johnson H, Guo J, Zhang X, Zhang H, Simoulis A, Wu A BMC Med. 2020; 18(1):376.

PMID: 33256740 PMC: 7706045. DOI: 10.1186/s12916-020-01834-0.

References

de Kok J, Verhaegh G, Roelofs R, Hessels D, Kiemeney L, Aalders T . DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002; 62(9):2695-8. View

Roehl K, Antenor J, Catalona W . Serial biopsy results in prostate cancer screening study. J Urol. 2002; 167(6):2435-9. View

Veltri R, Miller M, ODowd G, Partin A . Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology. 2002; 60(4 Suppl 1):47-52. DOI: 10.1016/s0090-4295(02)01695-3. View

Carter H, Pearson J, Metter E, Brant L, Chan D, Andres R . Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267(16):2215-20. PMC: 3461837. View

Cooperberg M, Lubeck D, Mehta S, Carroll P . Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003; 170(6 Pt 2):S21-5. DOI: 10.1097/01.ju.0000095025.03331.c6. View

Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D . Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353(12):1224-35. DOI: 10.1056/NEJMoa051931. View

Thompson I, Ankerst D, Chi C, Goodman P, Tangen C, Lucia M . Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006; 98(8):529-34. DOI: 10.1093/jnci/djj131. View

Catalona W, Smith D, Ratliff T, Dodds K, Coplen D, Yuan J . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324(17):1156-61. DOI: 10.1056/NEJM199104253241702. View

10.

Marks L, Fradet Y, Deras I, Blase A, Mathis J, Aubin S . PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007; 69(3):532-5. DOI: 10.1016/j.urology.2006.12.014. View

11.

Haas G, Barry Delongchamps N, Jones R, Chandan V, Serio A, Vickers A . Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007; 99(19):1484-9. DOI: 10.1093/jnci/djm153. View

12.

Mitchell P, Parkin R, Kroh E, Fritz B, Wyman S, Pogosova-Agadjanyan E . Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513-8. PMC: 2492472. DOI: 10.1073/pnas.0804549105. View

13.

. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149(3):185-91. DOI: 10.7326/0003-4819-149-3-200808050-00008. View

14.

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R . Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009; 101(6):374-83. PMC: 2720697. DOI: 10.1093/jnci/djp001. View

15.

Schaefer A, Jung M, Mollenkopf H, Wagner I, Stephan C, Jentzmik F . Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2009; 126(5):1166-76. DOI: 10.1002/ijc.24827. View

16.

Theodorescu D, Schiffer E, Bauer H, Douwes F, Eichhorn F, Polley R . Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl. 2011; 2(4):556-570. PMC: 2744126. DOI: 10.1002/prca.200780082. View

17.

Le B, Griffin C, Loeb S, Carvalhal G, Kan D, Baumann N . [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol. 2010; 183(4):1355-9. PMC: 3537165. DOI: 10.1016/j.juro.2009.12.056. View

18.

Drake R, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A . In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res. 2010; 9(5):2109-16. PMC: 2869496. DOI: 10.1021/pr1001498. View

19.

Kosaka N, Iguchi H, Ochiya T . Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101(10):2087-92. PMC: 11159200. DOI: 10.1111/j.1349-7006.2010.01650.x. View

20.

Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A . Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 2010; 59(3):422-9. DOI: 10.1016/j.eururo.2010.11.044. View